glaxosmithkline plc-spon adr
Transactions by GLAXOSMITHKLINE PLC-SPON ADR (GSK) in the last 6 months
GlaxoSmithKline plc (LSE:GSK) announces a share repurchase program. Under the program, the company will repurchase up to 486,100,716 shares, representing 10% of its outstanding share capital. The minimum price which may be paid for each ordinary share is 25p. The maximum price which may be paid for each ordinary share shall be the higher of either an amount equal to 5% above the average market value of the company’s ordinary shares for the five business days immediately ...
Novartis AG (SWX:NOVN) entered into an agreement to acquire marketed oncology portfolio, related R&D activities and AKT inhibitor from GlaxoSmithKline plc (LSE:GSK) for $16 billion in cash on April 22, 2014. The consideration amount is subject to customary adjustment for levels of working capital. Up to $1.5 billion of the amount depends on the results of the COMBI-d trial. In the event of termination of transaction, GlaxoSmithKline has agreed to pay Novartis a termination ...
GlaxoSmithKline plc (LSE:GSK) entered into a share and business sale agreement to acquire global Vaccines business from Novartis AG (SWX:NOVN) for $7.1 billion on April 22, 2014. Under the terms of the agreement, Glaxo agreed to pay $5.25 billion at closing with subsequent potential milestone payments and ongoing royalties, including $450 million upon FDA regulatory approval for Novartis' MenABCWY vaccine product, $450 million in the event that Bexsero achieves an agreed ...
GlaxoSmithKline plc (LSE:GSK) agreed to sell Insto eye drops brand and manufacturing site at Bogor for approximately IDR 130 billion on March 28, 2014. GlaxoSmithKline will receive combined IDR 133 billion for its Insto eye drops brand and manufacturing site at Bogor. In a related transaction, GSK Consumer Healthcare Pte. Ltd paid IDR 465 billion to Sarasvati Venture Capital Ltd. for the 30% of the Indonesian Consumer Healthcare business it did not previously own. As ...
GlaxoSmithKline plc (LSE:GSK) acquired remaining 30% stake in consumer healthcare business in Indonesia for approximately IDR 470 billion on March 28, 2014. In a related transaction, GSK divested its Insto™ eye drops brand to Pharma Healthcare Pte. Ltd and agreed to divest its manufacturing site at Bogor, Indonesia, to PT Pharma Healthcare for a combined total of approximately IDR 130 billion. For the year ending December 31, 2013, consumer healthcare business reported ...
|3M Co||$144.31 USD||+0.42|
|Bayer AG||€101.21 EUR||0.00|
|Gilead Sciences Inc||$88.73 USD||-0.21|
|Novo Nordisk A/S||kr247.80 DKK||0.00|
|PepsiCo Inc||$89.85 USD||-0.25|
|View Industry Companies|